Fujifilm Adds to Biologics Capabilities
By

Fujifilm Diosynth Biotechnologies, a biologics contract development and manufacturing organization, has launched a new monoclonal antibody (mAb) platform, Saturn, which adds to its mAb development and manufacturing capabilities.

The Saturn mAb platform is an extension of Fujifilm Diosynth Biotechnologies’ Apollo mammalian expression platform, which was developed for high levels of recombinant protein expression. The Saturn mAb platform is designed to enable rapid access to manufacturing capacity. It is also designed to support processes already established in existing cell lines.

Source: Fujifilm Diosynth Biotechnologies

Leave a Reply

Your email address will not be published. Required fields are marked *